Clinical Report: Effects of Comorbid Type 2 Diabetes on Survival Rates in Solid Tumor Patients

Overview

This meta-analysis evaluates the impact of type 2 diabetes mellitus (T2DM) on the prognosis of solid tumor patients undergoing immune checkpoint inhibitor (ICI) therapy. Findings indicate that T2DM is associated with poorer overall survival and progression-free survival in these patients, particularly in lung cancer.

Background

The increasing prevalence of type 2 diabetes mellitus (T2DM) poses significant challenges in cancer treatment, particularly with immune checkpoint inhibitors (ICIs). Patients with T2DM may experience an immunosuppressive tumor microenvironment, potentially leading to diminished efficacy of ICIs. Understanding the relationship between T2DM and cancer treatment outcomes is crucial for optimizing therapeutic strategies.

Data Highlights

Key Findings

• Patients with T2DM receiving ICIs had poorer overall survival (OS) compared to non-T2DM patients (HR = 1.49).
• Progression-free survival (PFS) was also negatively impacted in T2DM patients (HR = 1.38).
• Subgroup analyses showed consistent poorer OS in T2DM patients regardless of sample size or type of survival analysis.
• No significant difference in PFS was observed in larger sample sizes or multivariate analyses.
• The findings suggest a need for further research to clarify the impact of glycemic control on ICI efficacy.

Clinical Implications

Highlight the importance of personalized treatment strategies for T2DM patients.

Conclusion

This meta-analysis highlights the association between T2DM and poorer survival outcomes in solid tumor patients treated with ICIs, particularly in lung cancer. However, the limited number of studies and inherent biases necessitate cautious interpretation of these findings.

Related Resources & Content

1. Cortellini et al, ASCO Post, 2021 -- Can Diabetes Affect the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Cancer?
2. Wankhede et al, ASCO Post, 2025 -- Association of Type 2 Diabetes With Colorectal Cancer Risk and Survival by Tumor Immunity Status
3. Fabio Conforti et al, ASCO Post, 2018 -- Survival in Male vs Female Patients Receiving Immune Checkpoint Inhibitors
4. ASCO Post, 2024 -- Risk of Immune Checkpoint Inhibitor–Induced Diabetes
5. ASCO Post, 2025 -- Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
6. ScienceDirect, 2024 -- The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
7. PMC, 2023 -- Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations
8. Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options - The ASCO Post
9. The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis - ScienceDirect
10. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations - PMC